Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura
复制标题
DOI：
10.1182/blood-2007-02-068999
复制
发表时间：
2007-10-15
期刊：
影响因子：
20.3
通讯作者：
Arnadori, Sergio
中科院分区：
文献类型：
--
作者：
Stasi, Roberto;Del Poeta, Giovanni;Arnadori, Sergio
利妥昔单抗是一种抗CD 20单克隆抗体，已被用于治疗自身免疫性疾病，如特发性血小板减少性紫癜（ITP）。然而，其作用机制以及对细胞免疫的影响仍不清楚。我们研究了利妥昔单抗治疗后不同外周血T细胞亚群的变化、细胞凋亡谱以及CD 4（+）和CD 8（+）T细胞亚群的T细胞受体（TCR）β可变区（VB）基因使用的变化。该研究涉及30例接受利妥昔单抗治疗的慢性ITP患者，其中14例获得持久（> 6个月）反应。与对照组相比，ITP患者治疗前T细胞的异常包括Th 1/Th 2比值和Tc 1/Tc 2比值升高（P
Rituximab, an anti-CD20 monoclonal antibody, has been used to treat autoimmune disorders such as idiopathic thrombocytopenic purpura (ITP). However, its mechanisms of action as well as the effects on cellular immunity remain poorly defined. We investigated the changes of different peripheral blood T-cell subsets, the apoptosis profile, as well as the changes of T-cell receptor (TCR) beta-variable (VB) region gene usage of CD4(+) and CD8(+) T-cell subpopulations following rituximab therapy. The study involved 30 patients with chronic ITP who received rituximab, of whom 14 achieved a durable (> 6 months) response. Compared with the control group, pretreatment abnormalities of T cells in ITP patients included an increase of the Th1/Th2 ratio and of the Tc1/Tc2 ratios (P